ERBB2 and breast carcinoma: Everolimus in combination with exemestane has also been approved by the FDA and China's National Medical Products Administration, in postmenopausal patients with HR‐positive/HER2‐negative advanced breast cancer who failed letrozole or anastrozole therapy [16].